Protalix BioTherapeutics (PLX) Hit as EMA CHMP Denies MAA for Taliglucerase Alfa
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics (AMEX: PLX) shares are lower following news taliglucerase alfa did not get marketing approval from the EMA CHMP.
Shares are down about 14 percent ahead of the bell Friday.
Shares are down about 14 percent ahead of the bell Friday.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
